Close
FINDING CURES TOGETHER<sup>SM</sup>

Inaugural AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application

​Program 


Friday, June 22

Welcome and Opening Keynote Address
6-8 p.m.

Welcome from AACR Chief Executive Officer
Margaret Foti, American Association for Cancer Research, Philadelphia, Pennsylvania

Welcome from Scientific Committee Chair
Ari M. Melnick, Weill Cornell Medical College, New York, New York

Keynote Address
Michael A. Caligiuri, James Cancer Hospital & Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Keynote Address
Carl H. June, University of Pennsylvania, Philadelphia, Pennsylvania

Panel discussion

 
Opening Reception
8-10 p.m.


Saturday, June 23

Continental Breakfast
7-8 a.m.


Concurrent Sessions 1-2
7:15-8 a.m.

Concurrent Session 1: Canine Lymphoma as a Surrogate for Human Lymphomas: What Can We Learn from Canine Clinical Trials?
Session Cochairs: Luca Aresu, Department of Veterinary Science, Turin, Italy, and Kristy L. Richards, Cornell University, Ithaca, New York


Concurrent Session 2: What is the Optimal Therapeutic Approach to NHL in Adolescents and Young Adults: A Discussion from the Pediatric and Adult Perspectives
Session Chair: Lisa G. Roth, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York


Plenary Session 1: Are We Ready for Lymphoma MATCH Trials?
8-10:30 a.m.
Session Chair: Anas Younes, Memorial Sloan Kettering Cancer Center, New York, New York


Break
10:30-11 a.m.


Spotlight on Proffered Papers Session 1
11-11:30 a.m.


Poster Session A/Lunch

11:45 a.m.-1:45 p.m.


Plenary Session 2: Targeting the Epigenome of DLBCL
2-4 p.m.
Session Chair: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland


Break

4-4:30 p.m.


Plenary Session 3: Can Liquid Biopsies Replace Tissue and Be Used to Guide Clinical Decisions?
4:30-6:30 p.m.


Dinner on own
6:30 pm-


Sunday, June 24

Continental Breakfast
7-8 a.m.

Concurrent Sessions 3-4
7:15-8 a.m. 

Concurrent Session 3: What is the Current Role and Impact of CRISPR Screening to Define Therapeutic Targets in Lymphoma? Session Chair: Wendel Hans-Guido, Memorial Sloan Kettering Cancer Center, New York, New York


Concurrent Session 4: Genetic and Molecular Heterogeneity Between Western and Asian Lymphoma Patients

Session Chair: Wei-Li Zhao, Ruijin Hospital, Shanghai Institute of Hematology, Shanghai, China


Plenary Session 4: Will CAR T Cells Replace BMT as a Modality for NHL?
8-10:30 a.m.   
Session Chair: Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, New York

Break
10:30-11:00 a.m.


Spotlight on Proffered Papers Session 2

11-11:30 a.m.


Poster Session B/Lunch
11:45 a.m.-1:45 p.m.


Plenary Session 5: The Significance of Targeting the Microenvironment in Lymphoma
2-4 p.m.
Session Chair: Karine Tarte, University of Rennes, Rennes, France


Break
4-4:30 p.m


Plenary Session 6: Follicular Lymphoma: When to Treat and How to Define Early Disease
4:30-6:30 p.m.
Session Chair: Bertrand Nadel, Centre d'Immunologie de Marseille-Luminy, Marseille, France


Dinner on own
6:30 pm-


Monday, June 25

Continental Breakfast
7-8 a.m.

Concurrent Sessions 5-6
7:15-8 a.m.

Concurrent Session 5: What is the Molecular Basis and Most Promising Road Towards Molecular Targeted Therapies for Double-Hit Lymphoma?
Session Chair: David M. Weinstock, Dana-Farber Cancer Institute, Boston, Massachusetts


Concurrent Session 6: What do Mutation Profiles Teach Us About Rare Versus Common Forms of Lymphoma?

Session Chair: Sandeep S. Dave, Duke University, Durham, North Carolina


Plenary Session 7: How Do Clonal Dynamics and Tumor Heterogeneity Factor into Clinical Outcome and Therapy?
8-10:30 a.m.
Session Chair: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts


Break
10:30-11:00 a.m.


Spotlight on Proffered Papers Session 3
11-11:30 a.m.


Poster Session C/Lunch
11:45 a.m.-1:45 p.m.


Plenary Session 8: What is the Role for Checkpoint Protein Functionality and Therapeutic Blockade in Lymphoma?
2-4 p.m.
Session Chair: Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, Massachusetts


Break

4-4:30 p.m.


Plenary Session 9: Can We Improve the Outcome of Patients with PTCL?
4:30-6:30 p.m.
Session Chair: Kerry Savage, University of British Columbia, Vancouver, British Columbia, Canada

Dinner on own
6:30 pm-


Tuesday, June 26

Continental Breakfast
7-8 a.m.


Keynote Address
8-9 a.m.


Break
9-9:15 a.m.


Plenary Session 10: Transforming First-line Therapy for Hodgkin and Non-Hodgkin Lymphoma
9:15-11:45 a.m.
Session Chair: Thomas E. Witzig, Mayo Clinic College of Medicine, Rochester, Minnesota


Closing Remarks
11:45 a.m.-12 p.m.

Ari M. Melnick, Weill Cornell Medical College, New York, New York

Top of page